A Randomised Phase II Trial of Osimertinib with or without Stereotactic Radiosurgery for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

  • Alamgeer, Muhammad (Primary Chief Investigator (PCI))
  • Parakh, Sagun (Chief Investigator (CI))

Project: Research

Project Details

StatusActive
Effective start/end date20/03/19 → 19/03/24

Keywords

  • clinical trial
  • treatment efficacy
  • lung cancer
  • phase 2 trial